AcelRx Pharma Shares Fall 50.9%; Hearing FDA Staff Has Highlighted Co.'s Dsuvia Offers 'No Apparent Advantage Over Currently Available Therapies,' FDA Staff Highlights Risks Of Misplaced Tablets Of Dsuvia